Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial by Noordman, Bo Jan et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/183970
 
 
 
Please be advised that this information was generated on 2018-04-11 and may be subject to
change.
STUDY PROTOCOL Open Access
Neoadjuvant chemoradiotherapy plus
surgery versus active surveillance for
oesophageal cancer: a stepped-wedge
cluster randomised trial
Bo Jan Noordman1*, Bas P. L. Wijnhoven1, Sjoerd M. Lagarde1, Jurjen J. Boonstra2, Peter Paul L. O. Coene3,
Jan Willem T. Dekker4, Michael Doukas5, Ate van der Gaast6, Joos Heisterkamp7, Ewout A. Kouwenhoven8,
Grard A. P. Nieuwenhuijzen9, Jean-Pierre E. N. Pierie10, Camiel Rosman11, Johanna W. van Sandick12,
Maurice J. C. van der Sangen13, Meindert N. Sosef14, Manon C. W. Spaander15, Roelf Valkema16,
Edwin S. van der Zaag17, Ewout W. Steyerberg18, J. Jan B. van Lanschot1 and on behalf of the SANO-study group
Abstract
Background: Neoadjuvant chemoradiotherapy (nCRT) plus surgery is a standard treatment for locally advanced
oesophageal cancer. With this treatment, 29% of patients have a pathologically complete response in the resection
specimen. This provides the rationale for investigating an active surveillance approach. The aim of this study is to assess
the (cost-)effectiveness of active surveillance vs. standard oesophagectomy after nCRT for oesophageal cancer.
Methods: This is a phase-III multi-centre, stepped-wedge cluster randomised controlled trial. A total of 300 patients
with clinically complete response (cCR, i.e. no local or disseminated disease proven by histology) after nCRT will be
randomised to show non-inferiority of active surveillance to standard oesophagectomy (non-inferiority margin 15%,
intra-correlation coefficient 0.02, power 80%, 2-sided α 0.05, 12% drop-out). Patients will undergo a first
clinical response evaluation (CRE-I) 4–6 weeks after nCRT, consisting of endoscopy with bite-on-bite biopsies
of the primary tumour site and other suspected lesions. Clinically complete responders will undergo a second
CRE (CRE-II), 6–8 weeks after CRE-I. CRE-II will include 18F–FDG-PET-CT, followed by endoscopy with bite-on-
bite biopsies and ultra-endosonography plus fine needle aspiration of suspected lymph nodes and/or PET-
positive lesions. Patients with cCR at CRE-II will be assigned to oesophagectomy (first phase) or active surveillance
(second phase of the study). The duration of the first phase is determined randomly over the 12 centres, i.e., stepped-
wedge cluster design. Patients in the active surveillance arm will undergo diagnostic evaluations similar to CRE-II at 6/9/
12/16/20/24/30/36/48 and 60 months after nCRT. In this arm, oesophagectomy will be offered only to patients in whom
locoregional regrowth is highly suspected or proven, without distant dissemination. The main study parameter is overall
survival; secondary endpoints include percentage of patients who do not undergo surgery, quality of life,
clinical irresectability (cT4b) rate, radical resection rate, postoperative complications, progression-free survival,
distant dissemination rate, and cost-effectiveness. We hypothesise that active surveillance leads to non-inferior
survival, improved quality of life and a reduction in costs, compared to standard oesophagectomy.
Discussion: If active surveillance and surgery as needed after nCRT leads to non-inferior survival compared to
standard oesophagectomy, this organ-sparing approach can be implemented as a standard of care.
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Background
Oesophageal cancer is an aggressive disease with poor
outcomes after primary surgery [1]. Since the introduc-
tion of neoadjuvant chemo (radio) therapy, survival rates
have improved substantially [2]. The randomised Che-
moRadiotherapy for Oesophageal cancer followed by
Surgery Study (CROSS) showed an absolute 5-year over-
all survival benefit of 14% after neoadjuvant chemoradio-
therapy (nCRT) plus surgery, compared to surgery alone
[3, 4]. Moreover, after nCRT according to CROSS, 29%
of all patients (49% for squamous cell carcinoma [SCC]
and 23% for adenocarcinoma [AC]) had a pathologically
complete response (pCR) in the resection specimen [3].
This high pCR-rate provides the rationale to explore an
organ-sparing active surveillance approach after nCRT
since, intuitively, an oesophagectomy in patients with no
viable residual tumour does not improve oncological
outcome. In this organ-sparing treatment strategy, pa-
tients will undergo frequent diagnostic evaluations after
nCRT. An oesophagectomy will be performed only in
patients with a proven or high suspicion of locoregional
regrowth, in the absence of distant metastases. This
treatment strategy would have great advantages, espe-
cially given the perioperative morbidity and mortality,
and the lasting impact on patients’ health-related quality
of life (HRQOL) that is associated with oesophagectomy
[3, 5–9]. An active surveillance approach would not only
benefit patients who are cured by nCRT alone, but also
patients with undetectable distant metastases (i.e. micro-
metastases) after completion of nCRT. Currently, pa-
tients with occult distant metastases undergo standard
oesophagectomy. This theoretically is of no benefit, be-
cause distant metastases, which are the main determi-
nants of long-term survival, are below the detection
limit at the first clinical evaluation after nCRT. During
active surveillance, these occult metastases might be-
come clinically manifest, which will prevent patients
from a non-beneficial oesophagectomy.
At present, active surveillance is applied in selected
patients who refuse oesophagectomy or who are finally
considered unfit for surgery after nCRT [10–13]. Ex-
plorative retrospective studies in these patients show
promising results, with comparable long-term survival
for active surveillance vs immediate standard surgery
and comparable outcomes of postponed oesophagect-
omy in patients who develop a locoregional regrowth in
the absence of distant metastases [10–13].
In the recently completed diagnostic preSANO-trial,
endoscopy with bite-on-bite biopsies and ultra-
endosonography with fine needle aspiration (FNA) of
suspected lymph nodes for detection of locoregional
residual disease, combined with 18F–FDG PET-CT for
detection of interval metastases was adequate for clinical
response evaluation after nCRT for oesophageal cancer.
Using two rounds of clinical response evaluations (CREs),
sensitivity and specificity for differentiation between
tumour regression grade (TRG) 3–4 (i.e. > 10% vital cells)
and TRG 1 (i.e. no vital cells) residual tumour using en-
doscopy with bite-on-bite biopsies and FNA were 90%
and 72%, respectively. 18F–FDG PET-CT after nCRT de-
tected interval metastases in 10% of patients [14].
The results of the preSANO-trial in combination with
results in the literature on the clinical outcome of active
surveillance justify a phase-III trial, comparing active
surveillance with standard surgery in patients with a
clinically complete response after nCRT.
Objective
The aim of this study is to assess the (cost-)effectiveness
(including non-financial costs and survival) of active
surveillance after nCRT - as compared to standard sur-
gery - for patients with SCC or AC of the oesophagus or
oesophagogastric junction.
Methods
Study design
The SANO-trial is a phase III multi-centre, stepped-wedge,
cluster randomised controlled non-inferiority trial. This
design involves random sequential switch of clusters of par-
ticipating institutions from the control arm (standard
surgery) to the interventional arm (active surveillance).
Randomisation is performed at the institutional level, in-
stead of the individual level (Figs. 1 and 2) [15]. Twelve
high-volume centres in the Netherlands are participating in
this study (Erasmus Medical Centre, Rotterdam; Catharina
Cancer Institute, Eindhoven; Zuyderland Medical Centre,
Heerlen; Radboud University Medical Centre, Nijmegen;
Elisabeth Tweesteden Hospital, Tilburg; Gelre Hospital,
Apeldoorn; Leiden University Medical Centre, Leiden;
Maasstad Hospital, Rotterdam; Zorggroep Twente, Almelo;
Netherlands Cancer Institute, Amsterdam; Reinier de Graaf
Group, Delft; Medical Centre Leeuwarden). Based on these
12 participating centres, 6 clusters with comparable esti-
mated inclusion rates will be formed, each cluster compris-
ing 2 participating centres. Based on the expected
inclusion period of 36 months and the inclusion of
60 clinically complete responders from the preSANO
trial (see below; Statistical Analysis; Sample Size Cal-
culation), every 4.5 months one cluster will switch
from the control arm to the interventional arm. Clus-
ters will be determined by randomisation, but always
consist of a centre with high expected total inclusion
(≥45) and a centre with a lower (< 30) expected total
inclusion.
During the first 4.5 months of the trial, all centres will
provide standard immediate surgery and will gain ex-
perience in the performance of clinical response (and
surveillance) evaluations. After 4.5 months, a cluster of 2
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centres (Erasmus MC and Zuyderland Medical Centre)
with extensive experience in CREs and a large number
of patients included in the preSANO-trial, will start to
provide the novel strategy (active surveillance). After the
next 4.5 months, another cluster of 2 participating cen-
tres will be randomly assigned by the sponsor using a
computer-generated number sequence to begin with ac-
tive surveillance. This procedure will be repeated after
4.5 months until all clusters have crossed over into the
active surveillance arm. The final phase of the trial, with
all sites including patients in the active surveillance arm,
finishes approximately 9 months after the last cluster of
two sites have switched from the control arm to the
interventional arm (Fig. 2).
Patients who prefer the treatment that is not offered
as study treatment in that particular centre at that time
(e.g. active surveillance in a centre that has not yet
crossed over into the active surveillance group) cannot
be included in the trial. These patients will still be
treated in the same centre, but outside the trial.
Expected numbers of patients included in both study
arms during the different time periods and predefined
clusters with comparable expected numbers of inclu-
sions are shown in Fig. 2. Inclusion rate will be closely
monitored during the trial, and time periods will be
adjusted if the number of included patients differ sub-
stantially from the expectations.
Study population
Operable patients with locally advanced resectable SCC
or AC of the oesophagus or oesophagogastric junction
who are planned to undergo nCRT according to CROSS
followed by surgical resection are eligible for inclusion
[3]. Patients with language difficulties, dementia or
Fig. 1 Study algorithm. nCRT: neoadjuvant chemoradiotherapy; CRE: clinical response evaluation; cNCR: clinically non-complete response; cCR:
clinically complete response. *At this point the patient will be allocated to one of the two treatment arms, dependent on the institution in which
the actual treatment takes place. Randomisation will be performed at the institutional level (see §3.1 and §8.2). Patients will know their allocated
treatment at the moment of inclusion
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altered mental status prohibiting the understanding and
giving of informed consent and patients with non-FDG-
avid tumours at baseline will be excluded from participa-
tion in this study. Patients will have conventional pre-
treatment work-up (including F18-FDG PET-CT to
assess the avidity of the primary tumour).
Study algorithm (Table 1, Fig. 1, Fig. 3)
All included patients will undergo nCRT according to
CROSS (Carboplatin AUC 2 mg/mL per min, Pacli-
taxel 50 mg/m2 of body-surface area and 41.4 Gy of
concurrent radiotherapy in 23 fractions) [3]. Patients
will be re-staged after nCRT during CREs to select
those who may benefit from active surveillance. CREs
categorise patients as clinically complete responders
or clinically incomplete responders. Only patients in
whom no locoregional or disseminated disease is
proven (cCR) during CREs, will be included in the
comparative part of this trial.
CREs
Approximately 4–6 weeks after completion of nCRT all
included patients will undergo a first clinical response
evaluation (CRE-I) including oesophagogastroduodeno-
scopy (OGD) with at least 8 (random) biopsies, includ-
ing at least 4 bite-on-bite biopsies of the primary
tumour site and of any other suspected lesions. Patients
with (cyto) histological evidence of locoregional residual
disease during CRE-I will be offered a subsequent 18F–
FDG PET-CT to exclude disseminated disease and will
be offered immediate surgery (i.e. 6–8 weeks after com-
pletion of nCRT). Patients who are found to be cCR will
undergo a second CRE (CRE-II) 6–8 weeks after CRE-I
(i.e. 10–14 weeks after completion of nCRT). CRE-II will
include an 18F–FDG PET-CT, followed by OGD with
bite-on-bite biopsies of the primary tumour site and any
other suspected lesions, radial EUS and in case of PET-
positive lesions and/or suspected lymph nodes, even if
these lymph nodes are located directly adjacent to the
primary tumour site, linear EUS with FNA. The 18F–
FDG PET-CT during CRE-II must be available to guide
the endoscopist in taking biopsies and FNA during OGD
and EUS. Patients with (cyto)histological evidence of
locoregional residual disease or highly suspected locore-
gional residual disease on 18F–FDG PET-CT, and with-
out distant metastases during CRE-II will undergo
surgery immediately after CRE-II (i.e. 10–14 weeks after
completion of nCRT). Patients with distant metastases
will be referred for palliative care.
Patients without (cyto)histological evidence of re-
sidual disease during CRE-II (cCR), in the absence of
distant metastases, will be assigned to active surveil-
lance (experimental arm) or standard surgery (control
arm), according to the randomisation at the institu-
tional level.
Active surveillance
Patients in the active surveillance arm will undergo
active surveillance by 18F–FDG PET-CT, OGD with at
least 8 biopsies, including at least 4 bite-on-bite biopsies
Fig. 2 Stepped-wedge cluster design with addition of preSANO cCR-patients and sequential cross-over of 6 clusters comprising 2 centres
every 4.5 months
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and EUS plus FNA of all suspected lymph nodes at 6, 9,
12, 16, 20, 24, 30, 36, 48 and 60 months after completion
of nCRT or when symptoms or results of any diagnostic
test require shorter assessment intervals. Patients with
(cyto)histological evidence of disseminated disease dur-
ing active surveillance will be referred for palliative care
(Fig. 3).
Surgery
All patients in the control arm without distant metasta-
ses will be offered oesophagectomy after CRE-II,
whereas patients in the active surveillance arm will be
offered surgery only when locoregional regrowth is
highly suspected or proven, also without any signs of
distant dissemination (Fig. 3).
A transthoracic oesophagectomy or a transhiatal oeso-
phagectomy will be performed, depending on both
patient characteristics and local expertise and prefer-
ence. Open, hybrid and completely minimally invasive
techniques are allowed. At least 15 lymph nodes should
be harvested in every patient. An en-bloc resection of
the primary tumour and the regional lymph nodes
should be carried out including a standard dissection
of the lymph nodes around the coeliac axis (separ-
ately collected for nodes along the left gastric, com-
mon hepatic and splenic artery). In the chest, at least
the right paratracheal, subcarinal and para-
oesophageal lymph nodes should be harvested.
Pathology
All CRE- and surveillance biopsies will be assessed by ex-
pert GI pathologists. Initially, all biopsies will be analysed
based on the regular HE-slides (which contains two or
three levels). If analysis at these levels reveals obvious vital
tumour, the biopsy will be classified (diagnosed) as posi-
tive. If the assessment of this HE-slide is negative for ma-
lignancy (no malignancy), deeper sections will be
performed (two or three additional levels, depending on
the amount of tissue on the paraffin block). In case of
doubt regarding the presence of tumour (cells) after ana-
lysis of a biopsy at the aforementioned additional levels,
extra dPAS and (pan)keratin staining will be performed.
In case of an originally diagnosed signet-ring cell carcin-
oma or a poorly cohesive carcinoma with mucin produc-
tion, analysis at three additional (deeper) levels and dPAS
and keratin staining will be performed consistently.
Only the CRE- and surveillance biopsies with uncer-
tain outcome will be revised at the Department of Path-
ology of the Erasmus MC following the same strategy.
The resection specimens will be assessed using the 7th
edition of the UICC TNM cancer staging. Microscopic-
ally radical resection (R0) will be defined as a tumour-
free resection margin (margin > 1 mm not required).
Also, prepTNM staging will be estimated as described
earlier [16]. Tumour regression grade (TRG) will be
determined according to the modified Mandard classifi-
cation (TRG 1 to 4) [14].
Table 1 Study algorithm
Pretreatment CRE-I
(4–6 weeks
after nCRT)
CRE-II
(10–14 weeks
after nCRT)
Standard surgery arm
(6, 9, 12, 16, 20, 24, 30, 36, 48
and 60 months after nCRT)
Active surveillance arm
(6, 9, 12, 16, 20, 24, 30, 36, 48
and 60 months after nCRT)
Informed consent X
Inclusion X
Treatment allocationh X
ECOG performance status X X X X X
Endoscopy with bite-on-bite biopsies X X X X
Radial EUS X X X
Linear EUS with FNA of suspected lymph
nodes
X X X
18F–FDG PET-CT (whole-body) X Xa Xb Xc Xb
Quality of Life (EQ-5D, QLQ-C30, QLC-OG25
en Cancer Worry Scale)
X X Xd Xd
Oesophagectomy Xe Xf All At indicationg
a18F–FDG PET-CT: during CRE-I, after OGD, only for clinically non-complete responders, to exclude disseminated disease
b18F–FDG PET-CT: during CRE-II and active surveillance, prior to OGD and EUS, for all patients (all were clinically complete responders during CRE-I) to guide
endoscopists in taken biopsies / FNA during OGD and EUS and to exclude disseminated disease
c PET-CT in the standard surgery arm will be performed at 12 and 24 months after nCRT only, to exclude disseminated disaese
dQuality of life will be assessed during the first 2 years only
e Only for patients with locoregional disease
f After CRE-II: Only for patients with cCR who are allocated to surgery
g Only for patients in whom a locoregional regrowth is highly suspected or proven, without any signs of distant dissemination
CRE: clinical response evaluation; nCRT: neoadjuvant chemoradiotherapy; ECOG: Eastern Cooperative Oncology Group EUS: endo-ultrasonograpy; FNA: fine needle
aspiraton. hAt this point the patient will be allocated to one of the two treatment arms, dependent on the institution. Randomisation has already been performed
at the institutional level and will be known to the patient at the moment of inclusion
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Centralised multidisciplinary tumour board
During CRE-I and CRE-II, positive (cyto)histology is
preferably available when offering a patient surgical
resection. However, during active surveillance we do
allow a centralised multidisciplinary tumour board
(MTB, Erasmus MC) to recommend surgical resection
in selected patients who have a high clinical / diagnostic
suspicion of tumour regrowth, despite repeatedly nega-
tive (cyto)histology. This centralised MTB will monitor
and decide on all such suspected patients from all par-
ticipating centres. The reason for offering surgical resec-
tion in patients with a (strong) clinical suspicion of
regrowth, but without positive (cyto)histology is to min-
imise the risk that a difficulty in confirming regrowth by
histology causes a delay that will permit a tumour re-
growth to expand into an irresectable stage. If for
instance the intensity of a hotspot on 18F–FDG PET-CT
substantially increases over time during surveillance but
positive (cyto)histology cannot be obtained, the MTB
can decide to recommend surgery.
Follow-up
Follow-up visits of patients in both study arms will occur at
6, 9, 12, 16, 20, 24, 30, 36, 48 and 60 months after comple-
tion of nCRT. Additional visits will be scheduled if com-
plaints will arise before the next visit. In cases of suspected
recurrence, thoraco-abdominal CT, PET-CT and/or upper
gastrointestinal endoscopy will be performed. In order to
accurately compare distant dissemination rates between
both treatment arms, 18F–FDG PET-CT scan will be per-
formed in all patients in the standard surgery arm after 1
and 2 years of follow-up, after which most (> 80% and >
Fig. 3 Expected distribution of patients. nCRT: neoadjuvant chemoradiotherapy; CRE: clinical response evaluation; S1: first surveillance evaluation;
S2: second surveillance evaluation etc. Treatment allocation*: randomisation will be performed at institutional level and will be known already at
the moment of inclusion; immediate surgery arm of randomisation not shown
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90%, resp.) distant metastases will likely have been detected
[17]. If a patient in the active surveillance will undergo post-
poned oesophagectomy due to a locoregional regrowth
without distant metastases, follow-up will be performed ac-
cording to the Dutch Guideline for oesophageal cancer [18].
Study parameters/endpoints
The main study parameter in this study is overall sur-
vival of patients with cCR at CRE-II (i.e. 10–14 weeks
after completion of nCRT). Secondary study parameters
include:
– The percentage of patients in the active surveillance
arm who do not undergo surgery (i.e. patients who
are cured by nCRT or who have occult distant
metastases during initial staging, which become
manifest during active surveillance);
– HRQOL as measured with EQ-5D [19], QLQ-C30
[20], QLC-OG25 [21] and Cancer Worry Scale [22]
questionnaires;
– Clinical irresectability (cT4b) rate; R0-resection rate
defined as percentage of patients within the entire
randomised population who undergo resection,
defined as a tumour-free resection margin;
– Postoperative morbidity/complications for all
randomised patients with cCR who undergo
resection, as defined by the Esophageal
Complications Consensus Group [23];
– Postoperative mortality for all patients with cCR
who undergo resection, defined as 90 day- and/or
in-hospital mortality;
– Progression-free survival, defined as the interval
between randomisation and the earliest occurrence
of disease progression resulting in primary (or
peroperative) irresectability of disease, locoregional
regrowth (after completion of therapy);
– Distant dissemination rate;
– Cost-effectiveness.
Safety and stopping rules
Delaying surgical resection in patients in the active sur-
veillance arm should neither lead to a significant reduc-
tion in tumour resectability and radical resection rate,
nor to a significant increase in postoperative mortality
and distant dissemination rate. Therefore, the following
parameters are closely monitored;
– Proportion of all patients in the active surveillance
arm that present with an irresectable or incurable
(T4b or R2) regrowth, in the absence of distant
metastases;
– Proportion of all patients in the active surveillance
arm that undergo a microscopically non-radical (R1)
resection;
– Postoperative morbidity; postoperative in-hospital
mortality in all patients in the active surveillance
arm, proportion of all patients in the active surveil-
lance arm with hospital stay > 60 days or who de-
velop postoperative trachea-neo-oesophageal fistula;
– Proportion of all patients in the active surveillance
arm that develop distant dissemination after 1 and 2
years of follow-up.
If outcomes of one or more of these parameters in the
active surveillance arm significantly exceed the outcomes
in the standard surgery arm or in the Dutch Upper-GI
Cancer Audit (DUCA) data 2016, all participating cen-
tres will be notified immediately and further inclusion
will be stopped [24]. Patients who have been already in-
cluded will be informed and offered the possibility of im-
mediate (high-priority) surgical resection, even in the
absence of suspicion of regrowth. Continuation of active
surveillance will also still be offered.
Statistical analysis
Sample size calculation
In the present phase-III study, we plan to randomise at
institutional level 300 patients with cCR during CRE-II
between active surveillance and standard surgical resec-
tion. Simulation of trial outcomes with expected equal
3-year overall survival rates of 67% in both trial arms
and an intra-correlation coefficient of 0.02 to account
for between-institution variation (inter-quartile range for
3-year overall survival rates of 63%–71%) indicates a
total sample size of 264 patients to show non-inferiority
of surveillance to standard surgery with 80% power [25].
Non-inferiority is defined as a 3-year survival rate that is
no more than 15 percentage points below the expected
67% 3-year survival rate among patients in the standard
surgery arm (data based on the CROSS-trial) [3, 4]. To
allow for a 12% drop-out (e.g. patients in the active
surveillance-arm who request immediate surgery in the
absence of clinically proven or suspected regrowth) 300
patients are required for randomisation. Based on pre-
liminary data from the current preSANO-trial, we
expect that 50% of all included patients will have cCR
during CRE-II, leading to a total required inclusion of
600 patients.
To reduce the number of newly included patients and
to optimally use the data from the preSANO-trial, all
recently (≥ May 2015) included patients with cCR during
CRE-II from the current preSANO-trial who underwent
bite-on-bite biopsies during CRE-I and CRE-II will be
included in the control arm (n = 60 patients). Assuming
a 50% cCR rate, the total number of required patients to
be newly included in the SANO-trial will drop from 600
to 480 patients. Consequently, patients with cCR are
randomised at an institutional level in a 3:5 ratio.
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No interim analyses are planned for survival outcomes.
Data analysis
The difference in survival over a 3-year horizon between
the control arm and the experimental treatment arm will
be analysed with a mixed-effects Cox regression model.
Use of a mixed regression model – including an
institution-level random effect – is required to capture
the potential between-institutional variation in survival
[26]. To correct for potential selection bias, the treat-
ment effect will be estimated with adjustment for prog-
nostic factors for survival, i.e. age, sex, histologic subtype
of tumour, clinical N stage, and WHO performance
score. We will also use the mixed-effects Cox regression
model to study potential differences in treatment effect
between subgroups of patients. Subgroups are prede-
fined according to age, sex, histologic subtype of tumour,
clinical N stage, and WHO performance score. HRQOL
data will be analysed according to the EuroQol, EORTC
and Cancer Worry Scale scoring manuals [19–22]. Re-
peated measurement analysis will be used to evaluate
within and between group differences. Data will be ana-
lysed following the intention-to-treat principle, including
protocol deviators. A per protocol analysis will be per-
formed as a secondary analysis.
Ethical and regulatory considerations
The study has been approved by the medical ethics
committee of the Erasmus MC (MEC2017–392) and
has been registered in the Netherlands Trial Register
(NTR 6803). The study will be conducted according
to the principles of the Declaration of Helsinki (10th
version, Fortaleza, 2013) and in accordance with the
Dutch Medical Research Involving Human Subjects
Act (WMO) and other applicable guidelines, regula-
tions and Acts. In each participating centre, the local
coordinating or principal investigator will be respon-
sible for recruitment, data collection, follow-up of
included patients, completion of case report forms
and adherence to the study protocol. The supervising
physician or any other physician of the multidisciplin-
ary team will inform subjects about the study and ask
for their consent using standard information letters
and informed consent forms. Both patient information
letters and informed consent forms are attached as
separate documents.
An independent safety committee will be established
to perform on-going safety surveillance and to perform
interim analyses to assess the safety data and the stop-
ping rules as described in “safety and stopping rules”.
Each stopping rule will be repeatedly tested when the
first 10, 20, 30 and 50 events for that particular stopping
rule have occurred (i.e. [ad 1 and 2] detection of
locoregional regrowth, [ad 3] the performance of delayed
surgery or [ad 4] the detection of distant metastases).
The project leader (JL) is responsible for the study
design and conduct of the trial, for the preparation of
the protocol and revisions and for preparation of case
report forms. Revisions of the study protocol will be
communicated to all local chief investigators. The Clin-
ical Trial Centre (CTC) of the Erasmus MC – Univer-
sity Medical Centre Rotterdam is responsible for the
data master file, data verification and randomisation.
Randomisation will be performed via a computer-
generated random numbers sequence. Data will be
collected using individual trial case numbers on stan-
dardised case report forms collated centrally by the
CTC. Patients will not be individually identifiable. The
final dataset will be available to all study investigators
but will not be analysed per centre. Authorships will be
defined following the International Committee of Med-
ical Journal Editors guidelines [27]. Results will be com-
municated via international conferences, via publications
and via the NTR.
Discussion
Trials comparing surgical and non-surgical treatment
modalities often fail due to low accrual if randomisa-
tion is at the patient level, which might be explained
by patient preferences for an intervention [28–30].
Therefore, a stepped-wedge cluster design is applied
in the present trial [31]. In a stepped-wedge design,
randomisation takes place at the institutional level,
and not at the patient level. Consequently, at the mo-
ment of inclusion patients know which treatment arm
they will be assigned to, thereby overcoming uncer-
tainty about which treatment patients will undergo.
We expect that this will improve patients’ willingness
to participate. When proven successful, the stepped-
wedge design might be used as a new standard for
comparing surgical with conservative treatments in
clinical trials.
We will include both patients with SCC and pa-
tients with AC, since SCC and AC both respond to
nCRT and no statistically significant differential effects
were found in the CROSS-trial. Both patients with
SCC and AC have a substantial pCR rate (49% and
23% in CROSS respectively) [3]. Moreover, prelimin-
ary results of the preSANO-trial suggests that residual
disease can be diagnosed with comparable accuracy in
patients with both histological subtypes.
Furthermore, in combination with the relatively low
frequency of toxicity of the CROSS-regimen (91%
completed the full nCRT-regimen), the high pCR-rate
supports the use of the relatively low radiation dose
of 41.4 Gy [3]. The beneficial effectivity/toxicity ratio
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is the rationale to apply the CROSS-regimen in the
SANO-trial, and not a definitive chemoradiotherapy
regimen (≥50 Gy of radiotherapy). The latter could
increase the pCR-rate, but probably at the cost of a
substantial increase in toxicity and postoperative com-
plications, leading to a less beneficial effectivity/tox-
icity ratio. It should be noted that postponement of
surgical resection, as will be performed in patients
who develop locoregional regrowth in the absence of
distant metastases, has been suggested to increase the
incidence of postoperative complications. However,
this phenomenon has been reported primarily after
treatment with high-dose of definitive chemoradio-
therapy (so called salvage esophagectomy) in low-
volume centres [32, 33]. The SANO-trial will reveal
whether this also applies to a lower dose of radiother-
apy (CROSS regimen) in high-volume centres.
If the SANO-trial shows that active surveillance after
nCRT for oesophageal cancer leads to non-inferior sur-
vival compared to standard oesophagectomy, this organ-
sparing approach could be implemented as a standard of
care. Of note, the French ESOSTRATE-trial is also com-
paring active surveillance with standard surgery in
patients with cCR after nCRT. The ESOSTRATE-trial
aims to include a total of 300 patients with SCC or AC
with cCR after nCRT https://clinicaltrials.gov/ct2/show/
NCT02551458. The primary endpoint is overall survival,
as in the SANO-trial. Combining results from the
ESOSTRATE-trial and the SANO-trial would lead to
more certainty. Recently, we have shown that 54% and
61% of all patients are willing to trade-off 15% and 10%
overall survival, respectively, to undergo active surveil-
lance instead of standard surgery [34]. Therefore, the
statistical power of the SANO-trial is for a non-
inferiority margin of 15%; combination with the French
ESOSTRATE-trial would reduce this margin to 10%.
Hence, the future combination of results with the
ESOSTRATE-trial is important to further increase our
knowledge of an active surveillance approach beyond
what we will learn from the SANO-trial only.
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